中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
12期
1535-1537
,共3页
Ezrin基因%胃癌%组织芯片%淋巴结转移
Ezrin基因%胃癌%組織芯片%淋巴結轉移
Ezrin기인%위암%조직심편%림파결전이
Ezrin gene%Gastric carcinoma%Tissues-micoarry%Lymphatic metastasis
目的 探讨细胞骨架蛋白Ezrin在胃癌组织芯片中的表达及临床意义.方法 利用组织芯片技术和免疫组化Envision法检测Ezrin蛋白在385例胃癌(包括114例淋巴结未转移的胃癌和271例淋巴结转移的胃癌)及40例距肿瘤7 cm的正常胃组织中Ezrin蛋白的表达情况.所有患者均经外科手术治疗,病理诊断明确,术前未经放、化疗.结果 Ezrin蛋白在胃癌中的阳性率为64.9％(250/385),而在正常胃黏膜组织中的阳性表达率为5.0％ (2/40),P＜0.05;在淋巴结未转移者中的阳性率为16.6％ (64/114),在淋巴结转移者中的阳性率为48.3％(186/271),P＜0.05.Ezrin蛋白在淋巴结转移性胃癌中的高表达高于非转移性胃癌[40.0％(154/385)比14.8％(57/385),P＜0.05];与胃癌仅侵犯至肌层者相比,胃癌侵犯至浆膜及浆膜外者Ezrin蛋白呈高表达[44.4％(171/385)比9.4％(36/385),P＜0.05].结论 胃癌组织中Ezrin蛋白的阳性表达明显高于正常胃组织,并与胃癌的浸润及转移相关.
目的 探討細胞骨架蛋白Ezrin在胃癌組織芯片中的錶達及臨床意義.方法 利用組織芯片技術和免疫組化Envision法檢測Ezrin蛋白在385例胃癌(包括114例淋巴結未轉移的胃癌和271例淋巴結轉移的胃癌)及40例距腫瘤7 cm的正常胃組織中Ezrin蛋白的錶達情況.所有患者均經外科手術治療,病理診斷明確,術前未經放、化療.結果 Ezrin蛋白在胃癌中的暘性率為64.9％(250/385),而在正常胃黏膜組織中的暘性錶達率為5.0％ (2/40),P＜0.05;在淋巴結未轉移者中的暘性率為16.6％ (64/114),在淋巴結轉移者中的暘性率為48.3％(186/271),P＜0.05.Ezrin蛋白在淋巴結轉移性胃癌中的高錶達高于非轉移性胃癌[40.0％(154/385)比14.8％(57/385),P＜0.05];與胃癌僅侵犯至肌層者相比,胃癌侵犯至漿膜及漿膜外者Ezrin蛋白呈高錶達[44.4％(171/385)比9.4％(36/385),P＜0.05].結論 胃癌組織中Ezrin蛋白的暘性錶達明顯高于正常胃組織,併與胃癌的浸潤及轉移相關.
목적 탐토세포골가단백Ezrin재위암조직심편중적표체급림상의의.방법 이용조직심편기술화면역조화Envision법검측Ezrin단백재385례위암(포괄114례림파결미전이적위암화271례림파결전이적위암)급40례거종류7 cm적정상위조직중Ezrin단백적표체정황.소유환자균경외과수술치료,병리진단명학,술전미경방、화료.결과 Ezrin단백재위암중적양성솔위64.9％(250/385),이재정상위점막조직중적양성표체솔위5.0％ (2/40),P＜0.05;재림파결미전이자중적양성솔위16.6％ (64/114),재림파결전이자중적양성솔위48.3％(186/271),P＜0.05.Ezrin단백재림파결전이성위암중적고표체고우비전이성위암[40.0％(154/385)비14.8％(57/385),P＜0.05];여위암부침범지기층자상비,위암침범지장막급장막외자Ezrin단백정고표체[44.4％(171/385)비9.4％(36/385),P＜0.05].결론 위암조직중Ezrin단백적양성표체명현고우정상위조직,병여위암적침윤급전이상관.
Objective To investigate the expression of Ezrin protein in gastric carcinoma and its clinicopathologic significance.Methods The expression of Ezrin protein was detected by Envision immunohistochemical method in tissues-microarry (TMA).There were 385 cases of gastric carcinoma [without lymphatic metastasis (n =114) and gastric carcinoma with lymphatic metastasis (n =271)].40 paraffin-embedded tissue blocks of normal gastric epithelium (＞7 cm away from the edge of the tumor) were selected as the control group.All patients with gastric cancer were treated surgically and diagnosed histologically without preoperative chemotherapy or radiotherapy.Results The positive expression rates of Ezrin were 64.9％ (250/385) in gastric carcinoma tissues and 5.0％ (2/40) in normal tissues ; the expression of Ezrin protein in gastric cancer was significantly higher than that in normal gastric mucosa(P ＜ 0.05) ; it was 16.6％ (64/114) in gastric carcinoma tissues without lymph node metastasis and 48.3％ (186/271) in those with lymph node metastasis.Ezrin protein expression was higher in metastatic gastric carcinoma than that in primary gastric carcinoma tissues [40.0％ (154/385) vs 14.8％ (57/385),P ＜ 0.05].Ezrin protein expression in gastric cancer invasion to serosa was higher than that in the muscle layer only [44.4％ (171/385) vs 9.4％ (36/385),P ＜ 0.05].Conclusions Ezrin may contribute to the invasion and metastasis of gastric carcinoma through enhancing or up-regulating Ezrin protein.
